Sanofi : Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon
Go back to Sanofi : Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon| BANCO SANTANDER S.A. (NYSE: SAN) | Delayed: 13.60 -0.11 (0.8%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.71 | 52 Week High | $5.58 | |||
| Open | $13.51 | 52 Week Low | $3.60 | |||
| Day High | $13.62 | P/E | N/A | |||
| Day Low | $13.48 | EPS | $0.00 | |||
| Volume | 7,047,778 | |||||
| SANOFI (NASDAQ: SNY) | Delayed: 41.60 -0.18 (0.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $41.78 | 52 Week High | $44.76 | |||
| Open | $42.27 | 52 Week Low | $36.81 | |||
| Day High | $42.47 | P/E | N/A | |||
| Day Low | $41.47 | EPS | $0.00 | |||
| Volume | 10,855,605 | |||||
